Gain Therapeutics, Inc. (GANX) |
|
3.23 0.2 (6.6%)
|
12-02 15:59 |
|
Open: |
3.04 |
Pre. Close: |
3.03 |
|
High:
|
3.25 |
Low:
|
3.01 |
|
Volume:
|
45,669 |
Market Cap:
|
38(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:23:04 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 4.01 One year: 4.69 |
| Support: |
Support1: 3.14 Support2: 2.96 |
| Resistance: |
Resistance1: 3.44 Resistance2: 4.01 |
| Pivot: |
3.1 |
| Moving Average: |
MA(5): 3.09 MA(20): 3.09
MA(100): 3.49  MA(250): 3.78 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 40.4 %D(3): 30.3 |
| RSI: |
RSI(14): 56.6 |
| 52-week: |
High: 6.69 Low: 2.32 |
| Average Vol(K): |
3-Month: 27 (K) 10-Days: 15 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GANX ] has closed It is unclear right now based on current values. 62.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.25 - 3.27 |
3.27 - 3.28 |
|
Low:
|
2.97 - 2.99 |
2.99 - 3.01 |
|
Close:
|
3.2 - 3.23 |
3.23 - 3.25 |
|
Company Description |
|
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland. |
Headline News |
Mon, 28 Nov 2022
Monday’s Top Analyst Upgrades and Downgrades: Activision Blizzard, Amazon, Deere, DraftKings, Meta Platforms, Redfin, Tyson Foods, Visa, Wynn Resorts and More - 24/7 Wall St.
Fri, 25 Nov 2022
Health Care Sector Update for 11/25/2022: SPPI,GANX,IINN - Nasdaq
Thu, 10 Nov 2022
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq
Fri, 04 Nov 2022
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates - Nasdaq
Mon, 26 Sep 2022
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons - Yahoo Finance
Tue, 20 Sep 2022
Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
8.74e+006 (%) |
|
% Held by Institutions
|
24.3 (%) |
|
Shares Short
|
65 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.637e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-10 |
|
Return on Assets (ttm)
|
787.9 |
|
Return on Equity (ttm)
|
-29 |
|
Qtrly Rev. Growth
|
152250 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.03 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-15 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
393.2 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
48380 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
